AstraZeneca and Daiichi Sankyo enter collaboration to develop and commercialise oncology treatment
LONDON: AstraZeneca has entered into a new global development and commercialisation agreement with Daiichi Sankyo Company Limited for DS-1062, Daiichi Sankyo’s proprietary trophoblast cell-surface antigen 2 (TROP2)-directed antibody drug conjugate (ADC) and potential new medicine for the treatment of multiple tumour types. DS-1062 is currently in development for the treatment of multiple tumours that commonly…